Tyra Biosciences Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
87
- Stock Symbol
-
TYRA
- Share Price
-
$20.02
- (As of Friday Closing)
Tyra Biosciences General Information
Description
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Contact Information
Website
www.tyra.bioCorporate Office
- 2656 State Street
- Carlsbad, CA 92008
- United States
Corporate Office
- 2656 State Street
- Carlsbad, CA 92008
- United States
Tyra Biosciences Stock Performance
As of 13-Nov-2026, Tyra Biosciences’s stock price is $20.02. Its current market cap is $1.38B with 69.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $20.02 | $19.77 | $14.84 - $40.65 | $1.38B | 69.1M | 835K | -$2.64 |
Tyra Biosciences Financials Summary
As of 30-Sep-2026, Tyra Biosciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,155,336 | 1,134,147 | 349,570 | 386,824 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (181,865) | (132,216) | (103,658) | (79,545) |
| Net Income | (169,819) | (119,947) | (86,481) | (69,134) |
| Total Assets | 727,526 | 282,609 | 363,558 | 225,857 |
| Total Debt | 5,464 | 5,810 | 6,222 | 6,496 |
Tyra Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tyra Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Tyra Biosciences Comparisons
Industry
Financing
Details
Tyra Biosciences Competitors (11)
One of Tyra Biosciences’s 11 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Everest Medicines | Formerly VC-backed | Shanghai, China | ||||
| Johnson&Johnson Innovative Medicine | Venture Capital-Backed | Raritan, NJ | ||||
| Relay Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Taiho Oncology | Corporation | Princeton, NJ |
Tyra Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tyra Biosciences Patents
Tyra Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217643-A1 | Methods of treating solid tumors having activating fgfr3 and fgfr4 gene alterations | Pending | 08-Apr-2025 | ||
| WO-2026165305-A1 | Fgfr3 inhibitors for use in a method of treating children with achondroplasia | Pending | 31-Jan-2025 | ||
| WO-2026147994-A1 | Wrn inhibitors and their uses | Pending | 30-Dec-2024 | ||
| WO-2026148002-A1 | Wrn inhibitors and their uses | Pending | 30-Dec-2024 | ||
| WO-2026143223-A2 | Fgfr inhibitors | Pending | 27-Dec-2024 | C07D471/04 |
Tyra Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tyra Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Tyra Biosciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.05 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Tyra Biosciences FAQs
-
When was Tyra Biosciences founded?
Tyra Biosciences was founded in 2018.
-
Where is Tyra Biosciences headquartered?
Tyra Biosciences is headquartered in Carlsbad, CA.
-
What is the size of Tyra Biosciences?
Tyra Biosciences has 87 total employees.
-
What industry is Tyra Biosciences in?
Tyra Biosciences’s primary industry is Drug Discovery.
-
Is Tyra Biosciences a private or public company?
Tyra Biosciences is a Public company.
-
What is Tyra Biosciences’s stock symbol?
The ticker symbol for Tyra Biosciences is TYRA.
-
What is the current stock price of Tyra Biosciences?
As of 13-Nov-2026 the stock price of Tyra Biosciences is $20.02.
-
What is the current market cap of Tyra Biosciences?
The current market capitalization of Tyra Biosciences is $1.38B.
-
Who are Tyra Biosciences’s competitors?
Voyager Therapeutics, Everest Medicines, Johnson&Johnson Innovative Medicine, Relay Therapeutics, and Taiho Oncology are some of the 11 competitors of Tyra Biosciences.
-
What is Tyra Biosciences’s annual earnings per share (EPS)?
Tyra Biosciences’s EPS for 12 months was -$2.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
